Clinical Evidence and Proposed Mechanisms of Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Class Effect?
Effective treatment for heart failure with preserved ejection fraction (HFpEF) is an unmet need in cardiovascular medicine. The pathophysiological drivers of HFpEF are complex, differing depending on phenotype, making a one-size-fits-all treatment approach unlikely. Remarkably, sodium–glucose cotran...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Radcliffe Medical Media
2022-06-01
|
| Series: | Cardiac Failure Review |
| Online Access: | https://www.cfrjournal.com/articleindex/cfr.2022.11 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850256381755523072 |
|---|---|
| author | Brent Deschaine Sahil Verma Hussein Rayatzadeh |
| author_facet | Brent Deschaine Sahil Verma Hussein Rayatzadeh |
| author_sort | Brent Deschaine |
| collection | DOAJ |
| description | Effective treatment for heart failure with preserved ejection fraction (HFpEF) is an unmet need in cardiovascular medicine. The pathophysiological drivers of HFpEF are complex, differing depending on phenotype, making a one-size-fits-all treatment approach unlikely. Remarkably, sodium–glucose cotransporter 2 inhibitors (SGLT2is) may be the first drug class to improve cardiovascular outcomes in HFpEF. Randomised controlled trials suggest a benefit in mortality, and demonstrate decreased hospitalisations and improvement in functional status. Limitations in trials exist, either due to small sample sizes, differing results between trials or decreased efficacy at higher ejection fractions. SGLT2is may provide a class effect by targeting various pathophysiological HFpEF mechanisms. Inhibition of SGLT2 and Na+/H+ exchanger 3 in the kidney promotes glycosuria, osmotic diuresis and natriuresis. The glucose deprivation activates sirtuins – protecting against oxidation and beneficially regulating metabolism. SGLT2is reduce excess epicardial adipose tissue and its deleterious adipokines. Na+/H+ exchanger 1 inhibition in the heart and lungs reduces sodium-induced calcium overload and pulmonary hypertension, respectively. |
| format | Article |
| id | doaj-art-98bee87b9d5f44629f82c381aee2fb6e |
| institution | OA Journals |
| issn | 2057-7540 2057-7559 |
| language | English |
| publishDate | 2022-06-01 |
| publisher | Radcliffe Medical Media |
| record_format | Article |
| series | Cardiac Failure Review |
| spelling | doaj-art-98bee87b9d5f44629f82c381aee2fb6e2025-08-20T01:56:39ZengRadcliffe Medical MediaCardiac Failure Review2057-75402057-75592022-06-01810.15420/cfr.2022.11Clinical Evidence and Proposed Mechanisms of Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Class Effect?Brent Deschaine0Sahil Verma1Hussein Rayatzadeh2University of Florida College of Medicine, Gainesville, FL, USFlorida State University College of Medicine, Tallahassee, FL, USFlorida State University College of Medicine, Tallahassee, FL, US; Tallahassee Research Institute, Tallahassee, FL, US; Southern Medical Group, Tallahassee, FL, USEffective treatment for heart failure with preserved ejection fraction (HFpEF) is an unmet need in cardiovascular medicine. The pathophysiological drivers of HFpEF are complex, differing depending on phenotype, making a one-size-fits-all treatment approach unlikely. Remarkably, sodium–glucose cotransporter 2 inhibitors (SGLT2is) may be the first drug class to improve cardiovascular outcomes in HFpEF. Randomised controlled trials suggest a benefit in mortality, and demonstrate decreased hospitalisations and improvement in functional status. Limitations in trials exist, either due to small sample sizes, differing results between trials or decreased efficacy at higher ejection fractions. SGLT2is may provide a class effect by targeting various pathophysiological HFpEF mechanisms. Inhibition of SGLT2 and Na+/H+ exchanger 3 in the kidney promotes glycosuria, osmotic diuresis and natriuresis. The glucose deprivation activates sirtuins – protecting against oxidation and beneficially regulating metabolism. SGLT2is reduce excess epicardial adipose tissue and its deleterious adipokines. Na+/H+ exchanger 1 inhibition in the heart and lungs reduces sodium-induced calcium overload and pulmonary hypertension, respectively.https://www.cfrjournal.com/articleindex/cfr.2022.11 |
| spellingShingle | Brent Deschaine Sahil Verma Hussein Rayatzadeh Clinical Evidence and Proposed Mechanisms of Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Class Effect? Cardiac Failure Review |
| title | Clinical Evidence and Proposed Mechanisms of Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Class Effect? |
| title_full | Clinical Evidence and Proposed Mechanisms of Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Class Effect? |
| title_fullStr | Clinical Evidence and Proposed Mechanisms of Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Class Effect? |
| title_full_unstemmed | Clinical Evidence and Proposed Mechanisms of Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Class Effect? |
| title_short | Clinical Evidence and Proposed Mechanisms of Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Class Effect? |
| title_sort | clinical evidence and proposed mechanisms of sodium glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction a class effect |
| url | https://www.cfrjournal.com/articleindex/cfr.2022.11 |
| work_keys_str_mv | AT brentdeschaine clinicalevidenceandproposedmechanismsofsodiumglucosecotransporter2inhibitorsinheartfailurewithpreservedejectionfractionaclasseffect AT sahilverma clinicalevidenceandproposedmechanismsofsodiumglucosecotransporter2inhibitorsinheartfailurewithpreservedejectionfractionaclasseffect AT husseinrayatzadeh clinicalevidenceandproposedmechanismsofsodiumglucosecotransporter2inhibitorsinheartfailurewithpreservedejectionfractionaclasseffect |